The International Longevity Centre UK (ILCUK) report highlights how Europe's aging population faces increasing health challenges due to immunosenescence, which reduces vaccine effectiveness and increases vulnerability to disease.

Influenza 2024–2025 season in France was characterized by prolonged duration, unusual co-circulation of all three viruses (A(H1N1)pdm09, A(H3N2), B/Victoria) with several subclades, and substantial healthcare impact.

The safety and efficacy profiles of available RSV vaccines, a critical consideration for their integration into public health strategies and clinical practice, remain uncertain.

ESWI held a very successful Roundtable on 15 September in Vienna, focusing on facilitating dialogue to improve influenza prevention, control and vaccine uptake.

Mucosal vaccines are designed to elicit both a strong systemic and mucosal immune response gaining importance as the next generation of vaccines

Superior protection against laboratory-confirmed influenza has been proved for high-dose inactivated influenza vaccine, as compared with the standard dose, among adults 65 years of age or older.

Misinformation about vaccines can hinder efforts to increase immunization rates.

The evolution of SARS-CoV-2 has resulted in antigenically distinct variants that challenge vaccine-induced immunity.